In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Navigating cell therapy manufacturing amid pandemic woes
An article featuring expert commentary from ICON's Tamie Joeckel on supply-chain strategies to help mitigate vulnerabilities in both autologous and allogeneic cell therapy manufacturing.
-
Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan
This published study conducted by ICON's Health Economics team and Bristol-Myers Squibb evaluates a cost-effective new treatment for melanoma patients in Japan.
-
Planning a managed access programme: Advice for clinical teams
Managed access programmes (MAPs) are often unfamiliar territory for clinical teams, as their purpose and regulatory environment are very different from randomised controlled trials. ICON's Veronica Gutierrez Martinez considers how Sponsors need to plan carefully before undertaking a MAP so that they have the resources, processes, and tools in place to support the inevitable demand.
-
The impact of influenza vaccination on the COVID-19 pandemic? Evidence and lessons for public health policies
ICON's Richard Pitman joins global public health experts to address the importance of flu vaccination programs amid the COVID-19 pandemic.
-
How to measure your patient-centric impact
A patient insight article on the benefit of patient centric clinical trial design.
-
Developing enhanced digital content to increase physician engagement
With in-person scientific congresses an impossibility for the foreseeable future, researchers and publishers have to adapt how they foster scientific exchange. Experts from ICON's Medical Communications team discuss how they are using enhanced media fit for the digital age.
-
-
Right, left and centre
An article featuring expert commentary from ICON's Gretchen Goller on the importance of including patients at every stage of drug development.
-
Innovation in oncology drug development: A focus on patient benefits
An article by ICON's Dr. Brian Huber that examines how innovation, from the development of targeted therapies to a revolution in clinical trial designs, puts an emphasis on patient centricity.
-
Decentralised and hybrid trials – the patient’s voice
A thought leadership article by ICON's Gretchen Goller on getting the patient perspective on clinical trial participation.
